A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer

A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer Including Melanoma and Non-Melanoma

This study seeks to correlate microbial sequencing data from a punch biopsy in patients with skin cancer both melanoma and non-melanoma.

Study Overview

• Status: Withdrawn
• Conditions: Skin Cancer; Melanoma (Skin); Basal Cell Carcinoma; Squamous Cell Carcinoma; Microbiome
• Intervention / Treatment: Other: Non-interventional

Detailed Description

The human Skin microbiome is a complex, interconnected web of microbes, living in a symbiotic relationship with their host. There are greater than ten times more bacteria on our bodies than there are human cells, all in a delicate and ever-changing balance to maintain a healthy skin microbiome. When this balance is disrupted, a condition known as dysbiosis, disease can occur. There is still a debate over whether dysbiosis is a cause of disease or a symptom of it. Naturally, since the microbiome has such a profound impact on human health, we want to study and learn as much about the microbiome as possible. By correlating this data with medical records for the patient's skin cancer, connections may begin to be drawn between organisms present in the microbiome of the skin microbiome, and skin cancer. Much like fingerprints, no microbiome is identical therefore the only chance we have at understanding disease is by looking at the skin microbiome and comparing the microorganisms on a patient with skin cancer biopsy and non-skin cancer biopsy.

• Study Type: Observational

Contacts and Locations

Study Locations

• United States
  • California
    • Ventura, California, United States, 93003
      • ProgenaBiome

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Adults 18 and older with a diagnosis of skin cancer

Description

Inclusion Criteria:

• Signed informed consent
• 18 years of age or older
• Diagnosis of skin cancer, both melanoma and non-melanoma
• Able/willing to have a skin punch biopsy in a non-cancerous location

Exclusion Criteria:

• Unable/unwilling to sign informed consent
• Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation of Skin Microbiome to Cancer via Relative Abundance Found in Microbiome Sequencing	Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the skin microbiome in both cancerous and non-cancerous areas. These data will then be compared to elucidate unique qualities of the microbiome in skin cancer.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Validation of sequencing methods	To validate the sequencing methods used to generate microbiome data	1 year

Collaborators and Investigators

• Sponsor: ProgenaBiome
• Investigators: Principal Investigator: Sabine Hazan, MD, ProgenaBiome

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2019
• Primary Completion (Estimated): October 1, 2020
• Study Completion (Estimated): December 1, 2020

Study Registration Dates

• First Submitted: September 18, 2019
• First Submitted That Met QC Criteria: September 19, 2019
• First Posted (Actual): September 23, 2019

Study Record Updates

• Last Update Posted (Estimated): June 5, 2025
• Last Update Submitted That Met QC Criteria: June 2, 2025
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Skin Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Neoplasms, Basal Cell; Carcinoma; Melanoma; Skin Neoplasms; Carcinoma, Basal Cell
• Other Study ID Numbers: PRG-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Only aggregated, deidentified data will be made available to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No